Clinical Trial Update: Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating inhaled iloprost (Ventavis) for patients with residual pulmonary hypertension after pulmonary embolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Meshalkin Research Institute of Pathology of Circulation | Conditions: Residual Pulmonary Hypertension | Phase 2 | Status: UNKNOWN